[{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 399 9500", "website": "https://www.tscan.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 154, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gavin  MacBeath Ph.D.", "age": 53, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 853513, "exercisedValue": 0, "unexercisedValue": 471064}, {"maxAge": 1, "name": "Ms. Ann  Hargraves", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shrikanta  Chattopadhyay M.D.", "title": "Senior VP & Head of Translational Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ray  Lockard M.B.A.", "title": "Senior Vice President & Head of Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jim  Murray", "title": "Senior VP & Head of Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Cagan  Gurer Ph.D.", "title": "Senior Vice President of Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chrystal U. Louis M.D., M.P.H.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.75, "open": 6.65, "dayLow": 6.65, "dayHigh": 7.14, "regularMarketPreviousClose": 6.75, "regularMarketOpen": 6.65, "regularMarketDayLow": 6.65, "regularMarketDayHigh": 7.14, "beta": 0.899, "forwardPE": -6.0701756, "volume": 250284, "regularMarketVolume": 250284, "averageVolume": 192222, "averageVolume10days": 281260, "averageDailyVolume10Day": 281260, "bid": 6.85, "ask": 6.95, "bidSize": 100, "askSize": 200, "marketCap": 331500512, "fiftyTwoWeekLow": 1.62, "fiftyTwoWeekHigh": 9.0, "priceToSalesTrailing12Months": 15.748991, "fiftyDayAverage": 6.9796, "twoHundredDayAverage": 4.5968, "currency": "USD", "enterpriseValue": 231733792, "floatShares": 21099768, "sharesOutstanding": 43628100, "sharesShort": 219413, "sharesShortPriorMonth": 187726, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0046, "heldPercentInsiders": 0.0088599995, "heldPercentInstitutions": 0.83138, "shortRatio": 1.05, "shortPercentOfFloat": 0.0057, "bookValue": 3.154, "priceToBook": 2.1940393, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -89218000, "trailingEps": -1.36, "forwardEps": -1.14, "enterpriseToRevenue": 11.009, "enterpriseToEbitda": -2.63, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TCRX", "underlyingSymbol": "TCRX", "shortName": "TScan Therapeutics, Inc.", "longName": "TScan Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626442200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "78cfed2a-5d5f-3a28-9bf2-d5f7bc0c36ba", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.92, "targetHighPrice": 15.0, "targetLowPrice": 9.0, "targetMeanPrice": 11.6, "targetMedianPrice": 10.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 192044000, "totalCashPerShare": 4.011, "ebitda": -88097000, "totalDebt": 92433000, "quickRatio": 6.44, "currentRatio": 6.514, "totalRevenue": 21049000, "debtToEquity": 61.268, "revenuePerShare": 0.321, "returnOnAssets": -0.24790001, "returnOnEquity": -0.71289, "freeCashflow": -41827624, "operatingCashflow": -61358000, "revenueGrowth": 1.33, "operatingMargins": -2.96173, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-19"}]